Getting_VVG what_DDQ you_PPY pay_VV0 for_IF The_AT US_NP1 Food_NN1 and_CC Drug_NN1 Administration_NN1 can_VM not_XX fulfil_VVI its_APPGE mandate_NN1 without_IW a_AT1 serious_JJ funding_NN1 boost_NN1 ._. 
The_AT US_NP1 Food_NN1 and_CC Drug_NN1 Administration_NN1 (_( FDA_NP1 )_) is_VBZ in_II capable_JJ new_JJ hands_NN2 ._. 
Its_APPGE commissioner_NN1 ,_, Margaret_NP1 Hamburg_NP1 ,_, a_AT1 Harvard-trained_JJ physician_NN1 six_MC months_NNT2 into_II her_APPGE tenure_NN1 ,_, brings_VVZ to_II the_AT job_NN1 both_RR a_AT1 broad_JJ experience_NN1 in_II science_NN1 ,_, public_JJ health_NN1 and_CC biosecurity_NN1 and_CC an_AT1 ability_NN1 to_TO handle_VVI multiple_NN1 ,_, simultaneous_JJ demands_NN2 --_NN1 a_AT1 skill_NN1 she_PPHS1 displayed_VVD as_CSA New_NP1 York_NP1 City_NN1 's_GE youngest_JJT health_NN1 commissioner_NN1 ._. 
For_IF all_DB her_APPGE abilities_NN2 ,_, however_RR ,_, Hamburg_NP1 is_VBZ struggling_VVG to_TO steer_VVI an_AT1 underpowered_JJ ship_NN1 that_CST is_VBZ loaded_VVN to_II the_AT gunwales_NN2 ._. 
The_AT 103-year-old_JJ agency_NN1 ,_, based_VVN in_II Silver_NP1 Spring_NN1 ,_, Maryland_NP1 ,_, has_VHZ never_RR before_RT had_VHN so_RG many_DA2 demands_NN2 placed_VVN on_II it_PPH1 ,_, nor_CC has_VHZ its_APPGE budget_NN1 ever_RR been_VBN so_RR constrained_VVN relative_II21 to_II22 its_APPGE duties_NN2 ._. 
Between_II 2001_MC and_CC 2007_MC ,_, for_REX21 example_REX22 ,_, the_AT number_NN1 of_IO US_NP1 food-manufacturing_JJ plants_NN2 under_II the_AT FDA_NP1 's_GE jurisdiction_NN1 increased_VVN from_II about_RG 51,000_MC to_II more_DAR than_CSN 65,000_MC ,_, yet_RR the_AT number_NN1 of_IO staff_NN in_II its_APPGE foods_NN2 programme_NN1 fell_VVD from_II 3,167_MC to_II 2,757_MC ._. 
At_II current_JJ inspection_NN1 rates_NN2 ,_, any_DD given_JJ domestic_JJ food_NN1 company_NN1 faces_VVZ a_AT1 less_DAR than_CSN one-in-four_MC chance_NN1 of_IO being_VBG inspected_VVN once_RR in_II seven_MC years_NNT2 ._. 
And_CC that_DD1 looks_VVZ frequent_JJ compared_VVN with_IW the_AT agency_NN1 's_VBZ estimated_VVN average_JJ inspection_NN1 rate_NN1 for_IF foreign_JJ manufacturers_NN2 of_IO medium-risk_JJ medical_JJ devices_NN2 :_: once_RR every_AT1 27_MC years_NNT2 ._. 
It_PPH1 is_VBZ true_JJ that_CST the_AT FDA_NP1 's_GE funding_NN1 has_VHZ been_VBN boosted_VVN since_II 1993_MC by_II user_NN1 fees_NN2 paid_VVN by_II drug-_NN1 and_CC device-makers_NN2 ._. 
In_II 2009_MC ,_, such_DA fees_NN2 amounted_VVD to_II nearly_RR 23%_NNU of_IO the_AT agency_NN1 's_GE $2.7-billion_NNU budget_NN1 ._. 
But_CCB this_DD1 influx_NN1 has_VHZ ,_, paradoxically_RR ,_, taken_VVN the_AT pressure_NN1 off_II Congress_NN1 to_TO fund_VVI the_AT many_DA2 mandates_NN2 it_PPH1 continues_VVZ to_TO heap_VVI on_II the_AT agency_NN1 ._. 
For_REX21 instance_REX22 ,_, the_AT FDA_NN1 is_VBZ expected_VVN to_TO monitor_VVI the_AT accuracy_NN1 of_IO direct-to-consumer_JJ advertisements_NN2 by_II drug_NN1 companies_NN2 ,_, and_CC the_AT promotional_JJ materials_NN2 they_PPHS2 send_VV0 to_II physicians_NN2 ._. 
